Zealand Pharma ends recruitment for phase III study of glepaglutide

A sufficient number of patients have been enrolled for Zealand Pharma's phase III trial with glepaglutide, which is a potential treatment of short bowel syndrome (SBS).
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

All of the necessary patients have been found and recruited for a phase III study of glepaglutide, which is a potential treatment of short bowel syndrome (SBS), Zealand Pharma announces in a press release on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading